Influenza virus is a major medical and veterinary health concern and causes global 
Introduction
Influenza type A ('flu) virus is a major health concern for humans and livestock animals. The mode of transmission is by the respiratory route. 'Flu infection occurs seasonally and can cause global pandemics. The most recent 'flu pandemic was the 2009 H1N1 subtype swine 'flu, which resulted in more than 18,000 deaths worldwide (Pasricha et al., 2013) . The treatment of 'flu infections is difficult, because the virus has an RNA segmented genome, which has a high potential to recombine and create new strains through a mechanism termed re-assortment (Treanor, 2004) . Other potential risks to human populations are the zoonotic avian (bird) and porcine (swine) 'flu viruses. Vaccination remains the most effective means to prevent and control infection (Grohskopf et al., 2011) . However, the lead time to vaccine production is around 9 months, efficacy is not always complete, only a fraction of the human population is vaccinated and although some vaccines have been trialled against avian 'flu, farm animals in general are not routinely vaccinated on a global scale. There is, therefore, the need for drugs to treat 'flu.
Currently there are two common types of anti-influenza drugs, based on their mechanism of action. The first class are neuraminidase inhibitors such as Oseltamivir (Tamiflu). The second class are virus ion-channel blockers, such as Amantadine (Symetrel). The effectiveness of Tamiflu has been questioned (Cohen, 2014) , and in any case emerging resistance of the influenza virus is leading to reduced effectiveness. The promise of peptide-based antiviral drugs is established by the Food and Drug Administration's (USA) approval of Enfuvirtidie against HIV (Cooper and Lange, 2004) . The mode of action of antiviral peptides falls into three categories which are: (i) entry blocker peptides, which inhibit viral attachment and virus-cell membrane fusion; (ii) viral envelope targeting peptides, which disrupt the viral envelope; (iii) viral polymerase peptides, which inhibit replication of virus genome inside the infected cell by interacting with viral polymerase (Skalickova et al., 2015) . In vitro, several viral diseases have been treated with peptides such as HIV (Lee et al., 2014) , (Pessi et al., 2009 ), hepatitis C (Abe et al., 2007) , herpes simplex (Jenssen, 2005) , (Jaishankar et al., 2015) , and influenza virus (Albericio and Kruger, 2012 , She et al., 2008 , Nicol et al., 2012 .
Infectivity of influenza A viruses, including the H1N1 subtype, is strongly inhibited by a peptide called FluPep (Nicol et al., 2012) . FluPep was originally identified as a sequence in tyrosine kinase inhibitor peptide (Tkip), thought to act as a mimic of the suppressor of cytokine signalling (SOCS) protein (Ahmed et al., 2009 ).
However, FluPep's antiviral activity doesn't depend on blocking suppressor of cytokine signalling, which is intracellular, but instead this peptide appears to exert its antiviral activity from the outside of the cell. Thus, addition of FluPep to cells in culture prevents infection by 'flu virus, as does intranasal delivery of the peptide in a murine model of human 'flu (Nicol et al., 2012) .
Noble metal nanoparticles possess a strong plasmon absorbance, which allows detection at very low levels, using a range of approaches, from absorbance , Haiss et al., 2007a to photothermal microscopy (Berciaud et al., 2004) and various extensions of the latter (Lasne et al., 2006 . Noble metal nanoparticles can be passivated and functionalised with biomolecules such that they possess the biological selectivity and specificity of the grafted biological functional entity (Duchesne et al., 2012) , which includes peptides (Maus et al., 2010) . Presentation of a functional peptide by means of a nanoparticle has a number of advantages. Thus, nanoparticle conjugation may enhance the solubility of the peptide, as well as enhance its biological activity of the peptide, for example, due of multivalent functionalisation of the nanoparticles. In addition, noble metals such as silver possesses antimicrobial activities (Galdiero et al., 2011 were measured using a SpectraMax Plus spectrophotometer (Molecular Devices, Wokingham, UK) and 384 well plates from Corning (Lowell, US) and the concentration of gold nanoparticles and of silver nanoparticles determined at 450 nm (Haiss et al., 2007b) and 392 nm (Paramelle et al., 2014) , respectively.
Synthesis of FluPep functionalised nanoparticles
Mix matrix ligands 70:30 (mole:mole) CVVVT-ol: HS-(CH2) 11 -EG 4 -OH were prepared as described (Duchesne et al., 2008a) (Duchesne et al., 2008a) and 10 x (100 mM NaNO 3 , 20 mM HEPES with Tween-20 (0.1 % v/v) pH 7.4
to silver nanoparticles , vortex mixed and the (gold or silver) nanoparticles placed on a rotating wheel for 24 h. Nanoparticles were concentrated 10-fold using 10 kDa Nanosep centrifugal filters (PALL Corp., Portsmouth, Hants, UK). Samples were then centrifuged for 7 min at 10000 rpm (~12,000 x g) and the gold nanoparticles diluted with 1 x PBST (PBS 0.05% (v/v) Tween-20) and silver nanoparticles with 1x (100 mM NaNO 3 , 20 mM HEPES). The nanoparticles were then further separated from excess ligands by applying them (100 µL) to a 5 mL Sephadex G25 gel filtration column with PBS as a mobile phase.
To functionalise the nanoparticles with FluPep ligand, this was incorporated into the initial ligand mix at the mole % indicated in the figure legends. However, the separation of free FluPep ligand (mwt 2967 Da) required, in addition to the final gel-filtration on Sephadex G25, six washes, each wash involving a 10-fold dilution of the nanoparticles on a 10 kDa cut off Nanosep filter. 
Ion-exchange chromatography
Ion-exchange chromatography was performed on homemade mini columns of diethylaminoethyl (DEAE) and carboxymethyl (CM) Sepharose (GE Healthcare Bio-Sciences AB, Sweden). The chromatography gel slurry was packed into a white pipette tip (200 µL) using half the filter as a frit and equilibrated in PBS. Capped nanoparticles were concentrated and exchanged into the appropriate buffer using a a 10 kDa cut off Nanosep centrifugal filter. The nanoparticles were then applied to the column, the unbound fraction was recovered. Columns were washed with PBS and eluted with 1 M NaCl and then 2 M NaCl in 8 mM Na 2 HPO 4 , 15 mM KH 2 PO 4 , pH 7.4.
Ligand exchange assay
Purified ligand capped nanoparticles, 57 µL, 33 µL 10X PBS, and 10 µL DTT solutions at different concentrations (or milliQ water when the required concentration of DTT was 0) were added to a 384 well plate. A blank well, which only contained 100 µL of milliQ water, was used as reference. Spectra were acquired on duplicate wells at indicated times.
Calculation of the aggregation parameter (AP)
The surface 
Results and Discussion

Stability of FluPep functionalised gold nanoparticles
The mix matrix ligand shell of 70:30 mole/mole peptidol and alkanethiol ethylene glycol assembled on gold nanoparticles has well characterised stability with respect to ligand exchange and non-specific binding (Duchesne et al., 2008a , Chen et al., 2012 , but the effect of incorporating the FluPep amino acid sequence at the Cterminus of the CVVVT matrix sequence is unknown. Since the molecular weight of FluPep ligand (2967 Da) is greater than that required for group separation on Sephadex G25 (1000 Da) additional purification by means of washes on a 10 kDa cut off Nanosep filter were included to ensure removal of any free FluPep ligand.
When up to 5% (mole/mole) FluPep ligand was incorporated in the ligand matrix, the gold nanoparticles still eluted in the void volume of the Sephadex G25 column, so did not bind non-specifically to this chromatography matrix and their uv-vis spectrum in PBS was identical to that of control mix matrix gold nanoparticles (Fig.   1A ). This indicates that the FluPep sequence did not reduce the stability of the gold nanoparticles under these standard conditions. A more stressful test is ligand exchange with small thiols (Chen et al., 2012 , Duchesne et al., 2008a , Schulz et al., 2016 , Schulz et al., 2013 . Ligand-exchange results in a ligand shell that is unable to prevent electrolyte-induced aggregation of the nanoparticles, demonstrated by a decrease in the plasmon absorption at 520 nm.
Gold nanoparticles with a ligand shell incorporating 5% (mole/mole) FluPep ligand had a very similar resistance to ligand exchange with DTT as the control mix matrix protected gold nanoparticles. Thus, their aggregation parameter was unchanged up to 5 mM DTT, even after 48 h incubation (Figs 1 B, C) . At 10 mM DTT after 48 h there was some evidence for ligand exchange, as the aggregation parameter was above 1.0 and at 25 mM DTT the ligand shell was clearly compromised.
Nanoparticles incorporating lesser amounts of FluPep ligand (0.1% to 3 % mole/mole) were no less stable (Figs S1A-F). Consequently, the incorporation up to 5% (mole/mole) FluPep ligand in the ligand mixture did not reduce the stability of the gold nanoparticles with respect to ligand exchange and such nanoparticles could be used in cell culture medium.
Purification of FluPep functionalised gold nanoparticles
To functionalise the nanoparticles, the peptide FluPep ligand was included in the ligand mix, its mole % in relation to the matrix ligand reflects its grafting density on the gold nanoparticles (Levy et al., 2006 , Duchesne et al., 2008a , Duchesne et al., 2012 , Paramelle et al., 2015 , Nieves et al., 2014 . This can be determined by chromatography targeting specifically the grafted function, which also provides a means to purify the functionalised gold nanoparticles from those not functionalised, when the mole % of the functional ligand is low. Thus, when 10% of the functionalised gold nanoparticles bind to the chromatography column, most of these (95 %) will possess just one grafted functional ligand (Levy et al., 2006 , Duchesne et al., 2008a . Since FluPep ligand, like FluPep, has a net charge at pH 7.4 of +6, cation-exchange chromatography was used to purify functionalised gold nanoparticles. Parallel chromatography was performed on the anion-exchanger DEAE-Sepharose to control for possible non-specific binding of FluPep ligand to Sepharose.
Mix matrix gold nanoparticles did not to CM Sepharose nor to DEAE Sepharose (Fig. S2) , as described previously (Duchesne et al., 2008a) . Similarly, when FluPep ligand was incorporated in the ligand shell there was no binding to DEAE Sepharose, indicating the absence of non-specific interactions with the chromatography resin (Fig. S2) . In contrast, the FluPep functionalised gold nanoparticles bound to CM Sepharose and were eluted by increasing the electrolyte concentration of the eluent (Fig. 2) . Thus, the FluPep functionalised gold nanoparticles ion-exchanged with a negatively charged resin, which is, therefore, other functional peptides (Nieves et al., 2014 , Paramelle et al., 2015 . Nonetheless, this straightforward purification of the functionalised gold nanoparticles means that the effects on influenza virus infectivity of mono-versus plurifunctionalisation can be determined. Moreover, since it is known that gold nanoparticles passivated with the mix matrix (70:30 molar ratio of SH-(CH 2 ) 11 EG 4 and CVVVT-ol) have an average of 1200 peptidols per nanoparticle (Duchesne et al., 2008a) , it is possible to estimate the average number of FluPep ligands grafted on the gold nanoparticles by simply using their mole % in the ligand mixture.
Anti-flu activity of FluPep and FluPep ligand
The MDCK are susceptible to both influenza type A and B viruses and are routinely used to measure 'flu virus infectivity. The principle is that following virus binding, virus will infect a cell, reproduce and lyse that cell; released virus then infects neighbouring cells, the overlay preventing long-range diffusion of virus. After three days, the area of lysed cells is visualised as a plaque that does not stain with toluidine blue. In control (no virus) and vehicle (DMSO) treated cells, the cell monolayer in the well was evenly stained (Fig. S3 ). In the presence of virus, there were substantial areas where cells had lysed and there was no staining. Virus titre was adjusted so that the cleared lysed cell areas corresponded to individual plaques, i.e., clear circles that could be distinguished from one another and so counted (corresponding to ~100 plaques/well). When FluPep was added with virus there was a reduction in the number of plaques and this was concentration-dependent (Fig   4, A) . Counting plaques in multiple experiments allowed the determination of the dose-response and the IC 50 . In these experiments the IC 50 of the original FluPep sequence was found to be of the order of 140 pM (Fig. 3) . This is less potent than described in the original publication, where an IC 50 of 14 pM was measured. The source of this discrepancy is unknown, but may relate to differences in cells such as passage number, and/or virus preparations. The FluPep ligand used to functionalise gold nanoparticles was slightly less potent, with an IC 50 of around 210 pM, suggesting that the N-terminal extension CVVVTAA reduced the antiviral activity (Fig 3 and Table 1 ).
Anti-flu activity of FluPep functionalised gold nanoparticles
The addition of control mix matrix passivated nanoparticles along with the influenza virus did not change the number of plaques (Fig. 4A) . Thus, these nanoparticles had no effect on viral infectivity. However, when purified mix matrix capped gold nanoparticles functionalised with 5 % (mole/mole) FluPep ligand were added with virus, there was a marked decrease in the number of plaques, i.e. reduced virus infectivity (Fig. 4A) . Thus, FluPep ligand's antiviral activity was maintained when it was conjugated to gold nanoparticles. Table 2 ). The nanoparticles were always purified by cationexchange chromatography (Fig. 2) , so in all cases nanoparticles had at least one (Tables 2 and 3 ). This is likely greater than any uncertainty in the estimation of concentration of FluPep ligand, which can be gauged from the departure of the data in (Fig. 2) from the ideal, which was described previously (Levy et al., 2006) . Therefore, these data suggest that as the number of FluPep ligands on the nanoparticle surface increases to two or more, they are less active.
However, the data also demonstrate that free FluPep and FluPep ligand are less active than nanoparticles grafted with a single FluPep ligand. One explanation for this is that monomeric FluPep is the active species, but the peptide may selfassociate to produce dimers/oligomers with lower activity with respect to inhibiting influenza virus infectivity. The hydrophobicity of the FluPep sequence could be an important factor in such self-association. Moreover, self-association of the FluPep sequence might be greater for FluPep on a nanoparticle surface. For example, the association of functional peptides grafted into a peptide ligand shell on nanoparticles with themselves has been observed directly previously (Duchesne et al., 2008b) . Alternatively, the targets for FluPep may be separated by a distance similar or greater than their average physical separation on the nanoparticle surface, resulting in only some of the grafted FluPep ligands on the nanoparticle surface being able to exert an antiviral activity.
Stability of FluPep functionalised silver nanoparticles
Silver has well-established anti-microbial properties. It was of interest to determine whether FluPep functionalised silver nanoparticles possessed a similar anti-flu activity to their gold counterparts. The mix matrix ligand shell has been shown to impart good stability to silver nanoparticles . First, the effect of incorporating FluPep into the ligand shell on nanoparticle stability was measured.
Similarly to gold nanoparticles, up to 5% (mole/mole) FluPep ligand incorporated into the ligand matrix had no discernible effect on the handling and purification of the silver nanoparticles: the silver nanoparticles did not bind non-specifically to Sephadex G25, as they eluted in the void volume and their uv-vis spectrum in PBS was indistinguishable from that of control mix matrix silver nanoparticles (Fig. 5A) .
When challenged by a small thiol, DTT, the silver nanoparticles passivated by the mix matrix ligand shell were somewhat more prone to ligand exchange than their gold counterparts. Thus, after 3 h and 6 h in 50 mM DTT a small increase in aggregation parameter was apparent (Fig. 5B) . After 24 h and 48 h, the aggregation parameter started to rise at 3 mM DTT, which was most pronounced at 48 h.
Importantly, the inclusion of 5% (mole/mole) FluPep ligand in their ligand shell did not change the stability of the silver nanoparticles with respect to DTT-mediated ligand exchange (Fig. 5C ).
Purification of the FluPep functionalised silver nanoparticles was achieved by cation-exchange chromatography on CM-Sepharose. As the percentage of FluPep incorporated into the ligand shell increased, so did the percentage of nanoparticles bound to CM-Sepharose (Fig. 6 ). This suggests that the mole % FluPep ligand in the initial mixture of ligands added to the nanoparticles reflects its incorporation into the ligand shell (Levy et al., 2006 , Duchesne et al., 2008a . Thus, similarly to gold nanoparticles, when 10 % of the total nanoparticle preparation bound to the CM-Sepharose column, ~95% of the bound nanoparticles will possess a single
FluPep ligand (Levy et al., 2006) ; at higher mole % of FluPep ligand and increasing proportion of the silver nanoparticles will incorporate more than one FluPep ligand.
Anti-flu activity of FluPep ligand incorporated to silver nanoparticles
Control mix matrix passivated silver nanoparticles had no effect on viral infectivity (Fig. 7) . It is the silver (Ag + ) ions that exert anti-microbial activity (Hsueh et al., 2015) . Thus, this result indicates that there is not a substantial release of Ag + ions from the silver nanoparticles during the experiment. This concurs well with our data (Fig. 5 ) and previously reported observations demonstrating that the mix matrix ligand shell imparts good stability to the silver nanoparticles.
Incorporation of FluPep ligand into the mix matrix ligand shell caused a marked reduction in number of plaques (Fig. 7A) . As the mole % of FluPep ligand in the ligand shell increased, so did the antiviral activity of these particles ( Fig. 7A and Table 4 ). Around 10% of silver nanoparticles functionalised with 0.03 % (mole/mole) FluPep ligand bind to the CM-Sepharose column, indicating that the majority of these will carry just a single FluPep ligand (Fig. 6) , so the nanoparticle concentration will equate to the FluPep ligand concentration. These nanoparticles are as potent as free FluPep and more potent than free FluPep ligand (Tables 1 and   4 ). However, FluPep ligand functionalised silver nanoparticles were less effective at inhibiting influenza virus infectivity than the corresponding gold nanoparticles (Tables 2 and 4 to be solubilised. Although a useful solvent, its use in therapies is problematic due to DMSO's potential adverse reactions in some individuals such as a sensation of burning, vesiculation, dryness of skin and local allergic reactions (Cavaletti et al., 2000 , Delatorre et al., 1981 , Worthley and Schott, 1969 . Thus, conjugation to nanoparticles may provide a means to deliver effectively and safely FluPep ligand with enhanced activity in a solvent-free formulation. Though the mix matrix ligand shell prevents the dissolution of the silver, its modification will reduce its effectiveness . Thus, it will be possible to design silver nanoparticles that act through FluPep ligand and released Ag + ions. The pulmonary route to deliver drugs against respiratory infections is well established, therefore, delivery of functionalised nanoparticles against 'flu viruses is highly feasible. In conclusion, nanoparticle formation of FluPep ligand or analogous peptides offers a route to new treatments for 'flu and other respiratory pathogens. 
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